Valneva (NASDAQ:VALN) Shares Gap Up – What’s Next?

Valneva SE Sponsored ADR (NASDAQ:VALN) shares gapped up prior to trading on Wednesday . The stock had previously closed at $10.25, but opened at $11.27. Valneva shares last traded at $11.13, with a volume of 4,671 shares.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen cut shares of Valneva from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $15.00.

Valneva Stock Up 1.3%

The company has a market capitalization of $956.65 million, a P/E ratio of -7.72 and a beta of 1.80. The company has a current ratio of 1.78, a quick ratio of 1.36 and a debt-to-equity ratio of 0.72. The stock’s fifty day moving average is $9.93 and its 200 day moving average is $9.63.

Institutional Trading of Valneva

Institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. purchased a new position in Valneva during the 4th quarter valued at about $44,000. Marex Group plc purchased a new stake in Valneva in the 2nd quarter worth approximately $64,000. XTX Topco Ltd bought a new stake in shares of Valneva in the 4th quarter worth approximately $94,000. VSM Wealth Advisory LLC increased its stake in shares of Valneva by 125.0% during the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after buying an additional 5,000 shares during the period. Finally, JPMorgan Chase & Co. bought a new position in shares of Valneva during the third quarter valued at approximately $124,000. 11.39% of the stock is currently owned by hedge funds and other institutional investors.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.